Results 61 to 70 of about 932,452 (224)

Purinergic Signaling in the Pathophysiology and Treatment of Huntington’s Disease

open access: yesFrontiers in Neuroscience, 2021
Huntington’s disease (HD) is a devastating, progressive, and fatal neurodegenerative disorder inherited in an autosomal dominant manner. This condition is characterized by motor dysfunction (chorea in the early stage, followed by bradykinesia, dystonia ...
Melissa Talita Wiprich   +4 more
doaj   +1 more source

Integrating UHPLC-MS/MS quantitative analysis and exogenous purine supplementation to elucidate the antidepressant mechanism of Chaigui granules by regulating purine metabolism

open access: yesJournal of Pharmaceutical Analysis, 2023
Chaigui granules (CG) are a compound composed of six herbal medicines with significant antidepressant effects. However, the antidepressant mechanism of CG remains unclear. In the present study, we attempted to elucidate the antidepressant mechanism of CG
Jiajun Chen   +8 more
doaj   +1 more source

Dysregulation of Astrocytic ATP/Adenosine Release in the Hippocampus Cause Cognitive and Affective Disorders: Molecular Mechanisms, Diagnosis, and Therapy

open access: yesMedComm
The gliotransmitter adenosine 5'‐triphosphate (ATP) and its enzymatic degradation product adenosine play a major role in orchestrating in the hippocampus cognitive and affective functions via P2 purinoceptors (P2X, P2Y) and P1 adenosine receptors (A1 ...
Peter Illes   +4 more
doaj   +1 more source

Potentiating Cancer Immune Therapy via Nanomaterials and Purinergic Signaling

open access: yes, 2022
This review conjugates the current knowledge of purinergic signaling in cancer biology with techniques involving nanomaterials to increase anticancer immune ...
Travagli, Alessia   +11 more
core   +1 more source

Disrupted TFEB/GDNF–cAMP/ATP Coupling Underlies Astrocytic Dysfunction and Depression in LRRK2 G2019S Parkinson's Mice

open access: yesAdvanced Science, EarlyView.
ABSTRACT The LRRK2 G2019S mutation, a Parkinson's disease–linked variant, has been associated with depression‐like phenotypes, but mechanisms remain unclear. We chart age‐dependent behavioral changes and astrocyte reactivity in G2019S mice and define a pathway connecting LRRK2 to TFEB/GDNF signaling, cellular energetics, and inflammation.
Longping Yao   +5 more
wiley   +1 more source

Purinergic signalling in neuroregeneration

open access: yesNeural Regeneration Research, 2015
Purinergic signalling, adenosine 5′-triphosphate (ATP) as an extracellular signalling molecule, was proposed in 1972 (Burnstock, 1972). However, it was not generally accepted until the early 1990s when receptors for ATP and its breakdown product adenosine were cloned and characterised (Ralevic and Burnstock, 1998).
openaire   +3 more sources

Purinergic signaling in inflammatory cells: P2 receptor expression, functional effects, and modulation of inflammatory responses

open access: yes, 2013
Extracellular ATP and related nucleotides promote a wide range of pathophysiological responses via activation of cell surface purinergic P2 receptors. Almost every cell type expresses P2 receptors and/or exhibit regulated release of ATP.
Van Crombruggen, Koen   +11 more
core   +1 more source

Exocytosis of ATP from astrocytes modulates phasic and tonic inhibition in the neocortex [PDF]

open access: yes, 2014
Communication between neuronal and glial cells is important for many brain functions. Astrocytes can modulate synaptic strength via Ca2+-stimulated release of various gliotransmitters, including glutamate and ATP. A physiological role of ATP release from
Lalo, Ulyana   +23 more
core   +2 more sources

Purinergic Signaling in Health and Disease [PDF]

open access: yes, 2020
Adenosine 5’-triphosphate (ATP) is one of the most abundant molecule in living cells serving as universal energy “currency.” After slow acceptance of the concept of the release and extracellular action of ATP, purinergic signaling is recognized as a ...

core   +2 more sources

SLC25A4high Hepatocytes Enhance Lifestyle Intervention Response in MASLD by Recruiting Eating Macrophages

open access: yesAdvanced Science, EarlyView.
SLC25A4high hepatocytes drive metabolic‐associated steatotic liver disease (MASLD) remission by recruiting lipid‐eating macrophages. The hepatocyte Slc25a4/PANX1/ATP/P2ry12 axis mediates find‐me signaling that triggers macrophage recruitment and efferocytosis, while recruited macrophages secrete GDF15 to activate hepatocyte PPARα and promote fatty acid
Yiting Qian   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy